EP0929535A1 - Verfahren und neue zwischenprodukte - Google Patents
Verfahren und neue zwischenprodukteInfo
- Publication number
- EP0929535A1 EP0929535A1 EP97941446A EP97941446A EP0929535A1 EP 0929535 A1 EP0929535 A1 EP 0929535A1 EP 97941446 A EP97941446 A EP 97941446A EP 97941446 A EP97941446 A EP 97941446A EP 0929535 A1 EP0929535 A1 EP 0929535A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compound
- substituted
- formula
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
Definitions
- This invention relates to the fields of pharmaceutical and organic chemistry and provides novel intermediates and processes useful for the preparation of cryptophycin compounds .
- Antimetabolites have been used for a number of years as chemotherapeutic agents in the treatment of cancer.
- a new class of antimetabolites, cryptophycin compounds are useful for disrupting the microtubule system and, thus, can be useful for the treatment of cancer.
- the novel processes and intermediates of this invention are important elements in providing an efficient route for preparing other cryptophycin intermediates.
- a special advantage provided is that the intermediates thus prepared have only minimal residual impurities. Ultimately, these intermediates can be linked to provide a total synthesis of cryptophycin compounds.
- a number of problems must be resolved in order to accomplish a large scale total synthesis of a complex molecule such as the cryptophycin molecule. It is difficult to obtain intervening intermediates of sufficient purity, to be able to handle the materials easily and to obtain reliable yields when processes are carried out on the scale needed to obtain the quantities of compounds needed for pharmaceutical purposes.
- novel intermediates and processes of this invention accomplish some of these goals.
- one of the processes permits removal of a protecting group to provide an intermediate that can now be isolated as a convenient white solid.
- the new coupling process results in unexpectedly greater yields and avoids what previously was an extra step of preparing a pentafluorophenyldiphenyl- phosphinic chloride coupling reagent.
- a rhodium-catalyzed process prepares a novel fragment, called Fragment C, that is useful for an alternative synthesis of cryptophycin compounds.
- Another process that is applicable to acid-and base sensitive products minimizes recrystallization and chromatography steps.
- the processes and intermediates of this invention are important advances in the synthesis of useful cryptophycin compounds. These advances include, but are not limited to, increased efficiency, decreased cost, and improved purity.
- this invention provides a novel intermediate of Formula XII
- R 6 is Cj-Ce alkyl, substituted (Cj-C 6 ) alkyl, (C 3 -C 8 ) cycloalkyl, substituted C 3 -C ⁇ cycloalkyl, a heteroaromatic or substituted heteroaromatic group, or a group of formula Ilia, Ill'or III":
- R 6a , R* 5 , and R 6c independently are H, halo or OR 18 ;
- R 15 , R 16 , and R 17 independently are hydrogen, halo, (d-
- R 18 and R 19 independently are hydrogen or C ⁇ -C 6 alkyl
- R 23 is hydrogen or (C ⁇ -C 3 ) alkyl
- Z is -(CH 2 ) n - or (C3-C5) cycloalkyl; n is 0, 1, or 2; and Z' is an aromatic or substituted aromatic group.
- this invention provides a process for preparing an intermediate of Formula XII as defined supra, comprising contacting a compound of the formula XII'
- this invention provides a new coupling process for preparing compounds of Formula XIII (known as Fragment A-B of the cryptophycins) :
- Ar is an aromatic or heteroaromatic group, or a substituted aromatic or heteroaromatic group;
- R 60 is an alcohol protecting group;
- R 3 is C ⁇ -C 6 alkyl;
- R* and R 5 are H; or
- R* and R 5 together form a second bond;
- R 6 is as defined supra; comprising contacting a compound of Formula XII as defined supra, with 1) a compound of Formula XV
- R A is d-C 6 alkyl, C ⁇ -C 6 aralkyl, or Ar; and 3) a base.
- this invention provides an improved process for preparing a compound of Formula XIII, as defined supra, comprising reacting a compound of Formula XII, as defined supra, with a compound of formula XV as defined supra, in the presence of 1) the coupling reagent diphenyl chlorophosphate [ (PhO) 2 P(0) Cl] ;and 2) an amine.
- Carboxyl activation via phosphorous based reagents is an often used method for the synthesis of amides and related compounds.
- FDPP pentafluorophenyl diphenylphosphinic chloride
- R 1 is halo, SR, OR, amino, mono or di- (Ci-C ⁇ -alkyl) amino, tri (C ⁇ -C 6 -alkyl) ammonium, C ⁇ -C 6 -alkylthio, di (C]-C 6 - alkyl) sulfoniu , C ⁇ -C 6 -alkylsulfonyl, or C ⁇ -C 6 - alkylphosphonyl; and
- R 2 is OH or SH; or R 1 and R 2 taken together form a second bond between C-18 and
- R is H, C ⁇ -C 6 alkyl, C]-C 6 alkanoyl or Ar;
- R 7 is H, C ⁇ -C 6 alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, benzyl, or benzyl substituted with up to three substituents independently selected from C ⁇ -C 6 -alkyl, halo, C ⁇ -C 6 -alkoxy, amino or NR 51 R 52 ; and
- R 8 is H or C ⁇ -C 6 alkyl
- R 7 and R ⁇ together form a C 3 -C ⁇ cycloalkyl ring;
- R 51 and R ⁇ 2 independently are C : -C 3 alkyl;
- R 9 is H, C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 -alkynyl or (C,-C 6 alkyl) C3-C5 cycloalkyl;
- R 10 is H or C ⁇ -Ce alkyl
- X is 0, NH or ⁇ C1-C3 alkyl )N-; and Y is C, 0, NH, S, SO, S0 2 or (C1-C3 alkyl)N-; comprising contacting 1) a compound of Formula XVI
- This invention also provides a process for preparing a compound of Formula XVII
- R' a is C ⁇ -C 6 alkyl, with a rhodium catalyst and hydrogen gas; and optionally hydrolyzing the product to obtain the compound wherein R' is hydrogen.
- this invention provides a process for preparing a compound of Formula XIX
- R 7 , R 8 , R 9 and R 10 independently are H or d-C 6 alkyl; R p is tert-butoxycarbonyl (BOC) or benzyloxycarbonyl; comprising contacting a compound of Formula XX
- this invention provides an improvement in the process for preparing a compound of formula XX by coupling a Fragment D compound of the formula:
- R 7 and R 8 are as defined supra, but provided R 7 and R 8 cannot be H, in an inert organic solvent; the improvement comprising using the coupling reagent l,l ' - carbonyldiimidazole (CDI) .
- CDI coupling reagent l,l ' - carbonyldiimidazole
- catalytic quantity refers to less than a stoichiometric amount, but an amount sufficient to achieve the desired results.
- the term is intended to have the meaning commonly understood in the art.
- alkyl refers to an alkyl group with the designated number of carbon atoms. It may be saturated or unsaturated, and branched or straight chain. "Lower alkyl” means a C 1 -C5 alkyl group. Examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, propenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec- butyl, methyl-substituted butyl groups, pentyl, tert-pentyl, sec-pentyl, methyl-substituted pentyl groups and the like.
- Substituted alkyl refers to a C ⁇ -C 6 alkyl group that may include up to three (3) substituents containing one or more heteroatoms. Examples of such substituents are OH, NH 2 , C0NH 2 , C0 2 H, P0 3 H 2 and S0 2 R 21 wherein R 21 is hydrogen, d- C 3 alkyl or aryl .
- the term “cycloalkyl” refers to a saturated C 3 -C 8 cycloalkyl group.
- a “substituted cycloalkyl group” refers to a cycloalkyl group having up to three C1-C3 alkyl, halo, or OR 21 substituents. The substituents may be attached at any available carbon atom. Cyclohexyl is an especially preferred cycloalkyl group.
- “Lower alkoxy” means a alkyl group bonded to an oxygen atom.
- allyl means a 2-propenyl group.
- allyl scavenger is commonly understood in the art. Preferred allyl scavengers are pyrrolidine, piperidine, morpholine, and 1, 3-dicarbonyl compounds. An especially preferred allyl scavenger is morpholine.
- halo refers to Cl, Br, F, or I .
- aromatic group and “heteroaromatic group” refer to common aromatic rings having 4n + 2 pi electrons in a monocyclic or bicyclic conjugated system.
- aryl refers to an aromatic group
- aralkyl refers to an aryl (C ⁇ -C c -alkyl) group. Examples of aromatic groups are phenyl, benzyl and naphthyl.
- Heteroaromatic groups will contain one or more oxygen, nitrogen and/or sulfur atoms in the ring. Examples of heteroaromatic groups include furyl, pyrrolyl, thienyl, pyridyl and the like.
- aromatic or heteroaromatic groups When the aromatic or heteroaromatic groups are substituted, they may have from one to three independently selected C1-C7 alkyl, C ⁇ -C&-alkoxy or halo substituents.
- the substituents may be attached at any available carbon atom.
- Especially preferred heterocyclic groups are
- amino protecting group refers to a standard amino protecting group that is either acid labile or can be removed under mildly basic to neutral conditions. Such groups are well known in the art. [See, for example, J.F. . McOmie, "Protective Groups in Organic Chemistry", Plenum Press, (London and New York, 1973); Greene, T.W.
- Peferred amino protecting groups are acid labile.
- An especially preferred amino protecting group for compounds of Formula XVII is tert-butoxycarbonyl ("BOC") .
- BOC tert-butoxycarbonyl
- the R 6 substituent in a Formula I compound contains an amino substituent, it must be protected using an amino protecting group.
- alcohol protecting group is one that is introduced during a portion of the synthetic process to protect an alcohol group that might otherwise react in the course of chemical manipulations. The group is then removed at a later stage of the synthesis. Reactions for the formation and removal of such protecting groups are described in a number of standard works, including the two references listed supra.
- a particularly useful alcohol protecting group is tert-butyldimethylsilyl (TBS) .
- TBS tert-butyldimethylsilyl
- the processes of this invention are preferably carried out in the presence of a solvent. Selection of an appropriate solvent is commonly understood in the art.
- An inert organic solvent such as N, N-dimethylformamide (DMF) , ethyl acetate, dichloromethane, toluene or acetonitrile, or a mixture thereof, is recommended.
- Epoxide ring means a three-membered ring whose backbone consists of two carbon and one oxygen atoms.
- Aziridine ring means a three-membered ring whose backbone consists of two carbon and one nitrogen atoms.
- Episulfide ring refers to a three-membered ring whose backbone consists of two carbon and one sulfur atoms.
- halogenation examples include the addition of hydrogen halides, free radical halogenation, etc. Such methods are known in the art.
- strong acid refers to an acid that has a pKa of 2 or less.
- a hydrohalic acid is most suitable.
- a preferred hydrohalic acid is hydrochloric acid.
- Other mineral acids, such as phosphoric and sulfuric, and organic acids, such as tosic and acetic, may also be used.
- base has its accepted meaning.
- a base is a compound that yields hydroxyl ions in water or the negative ion of a solvent; or a base is any molecule or ion that can combine with protons or hydrogen ions, i.e. a proton acceptor.
- the term includes, but is not limited to, N,N-diisopropylethylamine, carbonates, and other tertiary amines.
- TBS refers to a tert-butyldimethylsilyl group.
- Equations 2 and 3 are applicable to corresponding intermediates having various Ar, R 60 , and R 6 groups.
- N-diisopropylethylamine are the illustrated solvent-base used in equations 2 and 3, and in that of equation 4 infra, any nonparticipating solvent or solvent combination-base will be appropriate for the processes.
- Typical solvents include ethers, halogenated hydrocarbons, and esters.
- Typical bases include tertiary amines and carbonates. An especially preferred base for these processes is diisopropylethylamine .
- An especially preferred solvent for the process of eq. 4 is DMF. This process is especially useful because it provides improved yields. In addition, it makes it possible to use Ph 2 P(0)Cl, which is commercially available, to complete the macrolactamization.
- Compound 8a is a known compound. It has been prepared by the reaction of ethyl cyanoacetate with methyl iodide in the presence of sodium ethoxide, a, and sodium hydride.
- c [a) Hessler, J.C. J. Am. Chem. Soc. 1913, 35, 990. b)
- hydrolysis conditions for preparing Compound 10 from Compound 9a can be readily determined.
- Especially preferred hydrolysis agents are LiOH and NaOH.
- Equation 7 The new allyl ester deprotection process is illustrated by Equation 7:
- R , R , R 9 and R 10 have the meanings defined supra.
- the Pd(PPh 3 ), catalyst should be present in an amount less than about four (4) mole percent.
- the amount of Pd(PPh 3 ) 4 catalyst is less than two mole percent (2 %) . It is especially preferred that the amount of Pd(PPh 3 ), catalyst is about two tenths mole percent (0.2%) or less. In addition, using less catalyst provides a significant cost advantage.
- Equation 7 process is when R 9 is isobutyl, and R 10 is hydrogen.
- An especially preferred allyl scavenger is morpholine.
- Preferred solvents for the process of Equation 7 are tetrahydrofuran, acetone, alcohols, acetonitrile, and ethyl acetate.
- An especially preferred solvent is tetrahydrofuran .
- the use of the allyl ester as a protecting group for carboxylic acids is well known and has been the subject of reviews. Kocienski, P. J. Protecting Groups; Georg Thieme Verlag: Stuttgart, 1994; pp 139-154; Greene, T. W.; Wuts, P. G. M.
- Procedures A and B illustrate the isolation advantage of the new process over the prior art process:
- PROCEDURE A (Barrowl) :
- PROCEDURE B (new process) :
- Table 1 illustrates the yield advantage provided by the new process.
- Equation 7 can be run at a temperature of from about zero (0) to about seventy (70) degrees C.
- a preferred temperature is about 25°C.
- the necessary reaction time is related to the starting materials and operating temperature.
- the optimum reaction time for a given process is, as always, a compromise which is determined by considering the competing goals of throughput, which is favored by short reaction times, and maximum yield, which is favored by long reaction times.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2552196P | 1996-09-06 | 1996-09-06 | |
US25521P | 1996-09-06 | ||
PCT/US1997/015703 WO1998009955A1 (en) | 1996-09-06 | 1997-09-05 | Process and novel intermediates |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0929535A1 true EP0929535A1 (de) | 1999-07-21 |
EP0929535A4 EP0929535A4 (de) | 2001-05-23 |
Family
ID=21826566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97941446A Withdrawn EP0929535A4 (de) | 1996-09-06 | 1997-09-05 | Verfahren und neue zwischenprodukte |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0929535A4 (de) |
JP (1) | JP2001502298A (de) |
AU (1) | AU4335297A (de) |
CA (1) | CA2263764A1 (de) |
WO (1) | WO1998009955A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1930100A (en) * | 1998-12-07 | 2000-06-26 | Eli Lilly And Company | Crotylboration process to produce cryptophycin compounds |
EP2289549A3 (de) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunokonjugate für Krebsbehandlung |
CN102448927A (zh) * | 2009-04-01 | 2012-05-09 | 力奇制药公司 | 活性亚甲基基团的二甲基化的方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4739120A (en) * | 1986-08-21 | 1988-04-19 | The Dow Chemical Company | Process for the hydrogenation of nitriles to primary amines |
EP0383170A2 (de) * | 1989-02-11 | 1990-08-22 | Hoechst Aktiengesellschaft | Polymerfixiertes Methotrexat, Verfahren zur Herstellung und Verwendung |
EP0422566A1 (de) * | 1989-10-12 | 1991-04-17 | POLI INDUSTRIA CHIMICA S.p.A. | Verfahren zur Herstellung von 3-(L-Pyroglutamyl)-L-thiazolidin-4-carbonsäure-Derivaten |
EP0518295A2 (de) * | 1991-06-14 | 1992-12-16 | Millipore Corporation | Allylseitenkettenschütz in Peptidsynthese |
WO1995017959A1 (fr) * | 1993-12-28 | 1995-07-06 | Rhone-Poulenc Chimie | Catalyseur d'hydrogenation de nitriles en amines, son procede de preparation et procede d'hydrogenation en faisant application |
WO1996040184A1 (en) * | 1995-03-07 | 1996-12-19 | University Of Hawaii | New cryptophycins from synthesis |
WO1997031632A1 (en) * | 1996-02-27 | 1997-09-04 | Eli Lilly And Company | Pharmaceutical compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3567834A (en) * | 1969-06-16 | 1971-03-02 | Bristol Myers Co | Method of producing sedation |
DE69427706T2 (de) * | 1993-12-21 | 2001-10-25 | Univ Hawaii Honolulu | Cryptophycine |
-
1997
- 1997-09-05 CA CA002263764A patent/CA2263764A1/en not_active Abandoned
- 1997-09-05 EP EP97941446A patent/EP0929535A4/de not_active Withdrawn
- 1997-09-05 WO PCT/US1997/015703 patent/WO1998009955A1/en not_active Application Discontinuation
- 1997-09-05 JP JP10512955A patent/JP2001502298A/ja active Pending
- 1997-09-05 AU AU43352/97A patent/AU4335297A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4739120A (en) * | 1986-08-21 | 1988-04-19 | The Dow Chemical Company | Process for the hydrogenation of nitriles to primary amines |
EP0383170A2 (de) * | 1989-02-11 | 1990-08-22 | Hoechst Aktiengesellschaft | Polymerfixiertes Methotrexat, Verfahren zur Herstellung und Verwendung |
EP0422566A1 (de) * | 1989-10-12 | 1991-04-17 | POLI INDUSTRIA CHIMICA S.p.A. | Verfahren zur Herstellung von 3-(L-Pyroglutamyl)-L-thiazolidin-4-carbonsäure-Derivaten |
EP0518295A2 (de) * | 1991-06-14 | 1992-12-16 | Millipore Corporation | Allylseitenkettenschütz in Peptidsynthese |
WO1995017959A1 (fr) * | 1993-12-28 | 1995-07-06 | Rhone-Poulenc Chimie | Catalyseur d'hydrogenation de nitriles en amines, son procede de preparation et procede d'hydrogenation en faisant application |
WO1996040184A1 (en) * | 1995-03-07 | 1996-12-19 | University Of Hawaii | New cryptophycins from synthesis |
WO1997031632A1 (en) * | 1996-02-27 | 1997-09-04 | Eli Lilly And Company | Pharmaceutical compounds |
Non-Patent Citations (3)
Title |
---|
BARROW R A ET AL: "TOTAL SYNTHESIS OF CRYPTOPHYCINS. REVISION OF THE STRUCTURES OF CRYPTOPHYCINS A AND C" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 117, no. 9, 8 March 1995 (1995-03-08), pages 2479-2490, XP002066281 ISSN: 0002-7863 * |
SALAMONCZYK G ET AL: "TOTAL SYNTHESIS OF CRYPTOPHYCINS VIA A CHEMOENZYMATIC APPROACH" JOURNAL OF ORGANIC CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 61, no. 20, 1 October 1996 (1996-10-01), pages 6893-6900, XP000674616 ISSN: 0022-3263 * |
See also references of WO9809955A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0929535A4 (de) | 2001-05-23 |
JP2001502298A (ja) | 2001-02-20 |
WO1998009955A1 (en) | 1998-03-12 |
AU4335297A (en) | 1998-03-26 |
CA2263764A1 (en) | 1998-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7989653B2 (en) | Exo- and diastereo-selective syntheses of himbacine analogs | |
EP3248969B1 (de) | Verfahren zur herstellung vom n-[3-(aminomethyl)oxetan-3-yl]carbamate zwichenproductke | |
US8163933B2 (en) | Clean, high-yield preparation of S,S and R,S amino acid isosteres | |
JP4310271B2 (ja) | Gaba類似体のアシルオキシアルキル誘導体の合成法 | |
KR101294432B1 (ko) | 레닌 억제제 합성의 중간체로서의3-알킬-5-(4-알킬-5-옥소-테트라히드로푸란-2-일)피롤리딘-2-온 유도체 | |
RU2418785C2 (ru) | Способ получения ингибиторов ренина | |
JPS626718B2 (de) | ||
EP0929535A1 (de) | Verfahren und neue zwischenprodukte | |
US6610874B2 (en) | Processes and compositions for the production of chiral amino-nitriles | |
US20190256453A1 (en) | Methods and intermediates for synthesizing sk1-i | |
US6573388B1 (en) | Ethylaziridine derivatives and their preparation methods | |
EP0932601A1 (de) | Verfahren zur herstellung von pharmazeutika | |
EP1309550A1 (de) | Optisch aktive aziridin-2-carbonsäurederivate und ein verfahren zu ihrer herstellung | |
JPH09323960A (ja) | 3−アミノ−1,2−オキシランの製造方法 | |
JP2004509879A (ja) | 光学活性なエポキシドの製造プロセス | |
KR20030055304A (ko) | 보호된 1-(1-아미노알킬)-옥시란의 제조 방법 | |
JP2004026652A (ja) | β−アルコキシアクリロニトリル誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990303 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010405 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030408 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030331 |